AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36846742 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided lifestyle intervention (ACTIVATE) including 1 virtual group session, digital tools (wireless scale, self-monitoring app), access to self-paced content via a secure website, and 12 weekly texts to reinforce health risk messaging
Number of subjects: 35
Study 36846742 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 35
Study 33794181 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir (400 mg) and rilpivirine (600 mg) administered as two 2 mL intramuscular injections every 4 weeks for at least 96 weeks.
Number of subjects: 566
Study 33794181 — intervention group
Group type: COMPARATOR
Intervention: Standard care regimen (daily oral dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg for 20 weeks followed by continuation).
Number of subjects: 566
Study 33794181 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir and rilpivirine.
Number of subjects: 566
Study 33794181 — intervention group
Group type: COMPARATOR
Intervention: Standard care regimen.
Number of subjects: 566
Study 35276572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (imipramine)
Number of subjects: 418
Study 35276572 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (acceptance and commitment therapy)
Number of subjects: 418
Study 33912990 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional local infiltration
Number of subjects: 63
Study 33912990 — intervention group
Group type: COMPARATOR
Intervention: Comfort‐In (needleless jet anaesthetic device)
Number of subjects: 63
Study 34152059 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Fulvestrant
Number of subjects: 0
Study 34152059 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 0
Study 33091438 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (P)
Number of subjects: 60
Study 33091438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo (N)
Number of subjects: 60
Study 33091438 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study 35914657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast and frugal tree (FFT) analysis
Number of subjects: 1569
Study 35914657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge regression
Number of subjects: 1569
Study 35914657 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects falsely predicted as likely to progress to DNC
Number of subjects: 1569
Study 34102508 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 800 mg/200 mg alone (LR0)
Number of subjects: 110
Study 34102508 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa plus extended release (XR) ropinirole 2 mg (LR2)
Number of subjects: 110
Study 34102508 — intervention group
Group type: EXPERIMENTAL
Intervention: extended release (XR) ropinirole 4 mg (LR4)
Number of subjects: 110
Study 34102508 — intervention group
Group type: COMPARATOR
Intervention: placebo (PLC)
Number of subjects: 110
Study 34125996 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TR) with low game performance
Number of subjects: 124
Study 34125996 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home telerehabilitation (TR) with high game performance
Number of subjects: 124
Study 34125996 — intervention group
Group type: COMPARATOR
Intervention: In-clinic physiotherapy
Number of subjects: 124
Study 34125996 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal adjustment in TR patients with low game performance
Number of subjects: 124
Study 33591887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 300
Study 33591887 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 300
Study 33591887 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ASCVD risk
Number of subjects: 300
Study 33768675 — intervention group
Group type: EXPERIMENTAL
Intervention: dr. Bart app
Number of subjects: 427
Study 33768675 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 427
Study 34704709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plus 50 µg fentanyl (1 mL)
Number of subjects: 45
Study 34704709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plus 100 µg dexmedetomidine (1 mL)
Number of subjects: 45
Study 34704709 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% plus saline (control)
Number of subjects: 45
Study 36047623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth treatment
Number of subjects: 300
Study 34732236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) administered to intensive induction therapy on days 1, 4, and 7
Number of subjects: 252
Study 34732236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) administered once on day 1 (GO-1)
Number of subjects: 252
Study 34732236 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasdegib as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Number of subjects: 252
Study 34732236 — intervention group
Group type: COMPARATOR
Intervention: Placebo as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Number of subjects: 252
Study 32907619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine combined with low-dose prednisone and anticoagulation
Number of subjects: 426
Study 32907619 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 426
Study 32907619 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine combined with anticoagulant
Number of subjects: 426
Study 36201773 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational text messages and personalized breastfeeding support
Number of subjects: 300
Study 36201773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (weekly text messages inquiring about infant feeding method)
Number of subjects: 300
Study 36201773 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational text messages and personalized breastfeeding support (intervention)
Number of subjects: 300
Study 36201773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300
Study 34137863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute PVT
Number of subjects: 47
Study 34137863 — intervention group
Group type: COMPARATOR
Intervention: 10-minute PVT
Number of subjects: 47
Study 32398443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg/d
Number of subjects: 50
Study 32398443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34528705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1520
Study 32311312 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning model using extremely randomized trees classifier
Number of subjects: 263
Study 32311312 — intervention group
Group type: COMPARATOR
Intervention: Existing predictive scores (PRESTO-1, PRESTO-2, EVENT)
Number of subjects: 263
Study 36066168 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU/day cholecalciferol
Number of subjects: 60
Study 36066168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/day cholecalciferol
Number of subjects: 60
Study 36066168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 34747583 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 90
Study 34747583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 32298870 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward digit recall (BDR) training with anodal tDCS (10 min, 1 mA)
Number of subjects: 48
Study 32298870 — intervention group
Group type: COMPARATOR
Intervention: Backward digit recall (BDR) training with sham tDCS
Number of subjects: 48
Study 32298870 — intervention group
Group type: COMPARATOR
Intervention: Visual search training with sham tDCS
Number of subjects: 48
Study 32298870 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal or sham)
Number of subjects: 48
Study 35065036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg (study 1)
Number of subjects: 1854
Study 35065036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg (study 1)
Number of subjects: 1854
Study 35065036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg (study 2)
Number of subjects: 1854
Study 35065036 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg (study 2)
Number of subjects: 1854
Study 35065036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 1)
Number of subjects: 1854
Study 35065036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (study 2)
Number of subjects: 1854
Study 34950259 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS management
Number of subjects: 80
Study 34950259 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 80
Study 35388606 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks)
Number of subjects: 58
Study 35388606 — intervention group
Group type: COMPARATOR
Intervention: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks) + SM peeling (20% salicylic and 10% mandelic acid every 4 weeks for 16 weeks)
Number of subjects: 58
Study 33844651 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle intervention (8-week program including diet, sleep, exercise, relaxation guidance, probiotics, and phytonutrients)
Number of subjects: 43
Study 33844651 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and lifestyle intervention
Number of subjects: 43
Study 33844651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 36471273 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified remnant‐preserved ACLR (group M)
Number of subjects: 70
Study 36471273 — intervention group
Group type: COMPARATOR
Intervention: Non remnant‐preserved ACLR (group N)
Number of subjects: 70
Study 33268424 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMA strategy using one product-ready-to-use therapeutic food at a gradually tapered dose
Number of subjects: 890
Study 33268424 — intervention group
Group type: COMPARATOR
Intervention: Standard nutritional protocol
Number of subjects: 890
Study 33268424 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiMA strategy
Number of subjects: 890
Study 36401742 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless computer‐guided surgery (S‐CAIS)
Number of subjects: 29
Study 36401742 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CS)
Number of subjects: 29
Study 34062484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg b.i.d. p.o. until disease progression)
Number of subjects: 80
Study 34062484 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide (3 g/m2 i.v. days 1–3, every 21 days for ≤6 cycles)
Number of subjects: 80
Study 34062484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 80
Study 34062484 — intervention group
Group type: COMPARATOR
Intervention: Ifosfamide
Number of subjects: 80
Study 36179790 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-second MicroPulse Transscleral Laser Therapy (Total Energy 93.9J, Fluence 131.0J/cm2)
Number of subjects: 19
Study 36179790 — intervention group
Group type: COMPARATOR
Intervention: 100-second MicroPulse Transscleral Laser Therapy (Total Energy 78.25J, Fluence 109.2J/cm2)
Number of subjects: 19
Study 36179790 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-second MicroPulse Transscleral Laser Therapy
Number of subjects: 19
Study 36179790 — intervention group
Group type: COMPARATOR
Intervention: 100-second MicroPulse Transscleral Laser Therapy
Number of subjects: 19
Study 33999539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with alcohol use disorder and a previous suicide attempt with acute alcohol use
Number of subjects: 972
Study 33999539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anxiety disorders
Number of subjects: 972
Study 33999539 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of more than 2 suicide attempts in the past 3 years
Number of subjects: 972
Study 33999539 — intervention group
Group type: COMPARATOR
Intervention: Good prognosis group (all other patients)
Number of subjects: 972
Study 32090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1) levels at 1st assessment (1992-1993)
Number of subjects: 809
Study 32090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1) levels at 2nd assessment (2005-2006)
Number of subjects: 809
Study 32090434 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PAI-1 levels
Number of subjects: 809
Study 35985050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal walking (PMW) - 10 minutes after breakfast, lunch, and dinner
Number of subjects: 41
Study 35985050 — intervention group
Group type: COMPARATOR
Intervention: Continuous walking - 30 minutes of continuous exercise
Number of subjects: 41
Study 35985050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal walking (PMW)
Number of subjects: 41
Study 34014691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1144
Study 34014691 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1144
Study 32870153 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg perampanel fine granules (FG)
Number of subjects: 21
Study 32870153 — intervention group
Group type: COMPARATOR
Intervention: 4-mg perampanel tablet
Number of subjects: 21
Study 36142114 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (induced perceived social support)
Number of subjects: 135
Study 36142114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induced perceived social support)
Number of subjects: 135
Study 32418679 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent in the ED
Number of subjects: 825
Study 32418679 — intervention group
Group type: COMPARATOR
Intervention: Consent at follow-up
Number of subjects: 825
Study 32418679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain advice and adequate analgesia
Number of subjects: 825
Study 32418679 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate analgesia
Number of subjects: 825
Study 35790010 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 115
Study 35790010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-TBS dosage (1.91–2.07 mg/kg)
Number of subjects: 115
Study 35790010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-TBS dosage (4.27–4.88 mg/kg)
Number of subjects: 115
Study 32918641 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 impact on HIV care
Number of subjects: 100
Study 32918641 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of risk
Number of subjects: 100
Study 32918641 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on ART adherence
Number of subjects: 100
Study 32918641 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback
Number of subjects: 100
Study 32652786 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowering communities with nutritional knowledge
Number of subjects: 0
Study 32652786 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control site without intervention)
Number of subjects: 0
Study 32652786 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (both sites)
Number of subjects: 0
Study 35627765 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-and self-compassion-based intervention (MSCBI)
Number of subjects: 24
Study 35627765 — intervention group
Group type: COMPARATOR
Intervention: Workplace Stress Management Intervention
Number of subjects: 24
Study 34081848 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (1 year of oral treatment)
Number of subjects: 1836
Study 34081848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 year of treatment)
Number of subjects: 1836
Study 34081848 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 1836
Study 34081848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1836
Study 32656869 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal radiofrequency
Number of subjects: 62
Study 32656869 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 62
Study 36244075 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on FLAIR sequences
Number of subjects: 113
Study 36244075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor location on the supratentorial region
Number of subjects: 113
Study 33184855 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Assisted Walking Program (IAWP)
Number of subjects: 387
Study 33184855 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care
Number of subjects: 387
Study 36132549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (ARNI)
Number of subjects: 0
Study 36132549 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (ACEI)
Number of subjects: 0
Study 33504633 — intervention group
Group type: EXPERIMENTAL
Intervention: Women presenting with ACS
Number of subjects: 21374
Study 32546421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) diet (GI < 35)
Number of subjects: 52
Study 32546421 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) diet (GI > 70)
Number of subjects: 52
Study 32546421 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC)
Number of subjects: 52
Study 32546421 — intervention group
Group type: COMPARATOR
Intervention: Moderate Glycemic Index (GI = 55–58) control diet
Number of subjects: 52
Study 35407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group (IIG) - auditory training following binaural hearing aid fitting, 14-day self-study program.
Number of subjects: 177
Study 35407372 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention Group (DIG) - control group, no immediate auditory training.
Number of subjects: 177
Study 35407372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IIG and DIG)
Number of subjects: 177
Study 35407372 — intervention group
Group type: EXPERIMENTAL
Intervention: IIG
Number of subjects: 177
Study 32513308 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 human convalescent plasma (200 - 250 mL)
Number of subjects: 129
Study 32513308 — intervention group
Group type: COMPARATOR
Intervention: Control plasma (200 - 250 mL)
Number of subjects: 129
Study 32513308 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 human convalescent plasma
Number of subjects: 129
Study 32513308 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 129
Study 34462998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% dietary arachidonic acid supplementation
Number of subjects: 24
Study 34462998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dietary arachidonic acid supplementation
Number of subjects: 24
Study 34462998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% dietary arachidonic acid supplementation
Number of subjects: 24
Study 34462998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arachidonic acid supplementation)
Number of subjects: 24
Study 35848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred, nurse-led follow-up programme
Number of subjects: 214
Study 35848783 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 214
Study 35848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (self-reported adherence)
Number of subjects: 214
Study 35848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Framingham risk score)
Number of subjects: 214
Study 36216361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (5 × 10^10 CFU, n = 39)
Number of subjects: 80
Study 36216361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 41)
Number of subjects: 80
Study 36216361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536
Number of subjects: 80
Study 36216361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32936322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-axis rotational angiography (RA)
Number of subjects: 67
Study 32936322 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography (CA)
Number of subjects: 67
Study 35331498 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use (COC, n=9)
Number of subjects: 19
Study 35331498 — intervention group
Group type: COMPARATOR
Intervention: No hormonal contraception use (NHC, n=10)
Number of subjects: 19
Study 32402259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 489
Study 33794808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention (accelerometer, in-person teaching session, gain-framed text messages) for 12 weeks
Number of subjects: 40
Study 33794808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention
Number of subjects: 40
Study 33794808 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 40
Study 32026822 — intervention group
Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire Short Form (IPAQ-SF)
Number of subjects: 64
Study 32026822 — intervention group
Group type: COMPARATOR
Intervention: wGT3X-BT triaxial accelerometer (ActiGraph)
Number of subjects: 64
Study 35411611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 5, 10, and 20 μg once daily for 6 weeks
Number of subjects: 23
Study 35411611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 35411611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 23
Study 33188713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8mg/kg every 2 weeks
Number of subjects: 625
Study 33188713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 36569174 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive psychological and psychiatric support for 2 months
Number of subjects: 193